Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579421 · ClinicalTrials.gov registry record · NA
Hormones and Reduction in Co-users of Marijuana and Nicotine
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT02579421: Completed NA study, sponsored by University of Minnesota.
NCT02579421 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02579421, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the role of progesterone (a naturally occurring hormone found in both men and women) on reducing marijuana use. The investigators will see if progesterone effects impulsivity, withdrawal, mood and stress during marijuana cessation.
Primary Outcome
Marijuana use as defined by the TLFB at the week 4 visit relative to the baseline visit.
Interventions
- DRUG placebo
- DRUG Progesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-07-27 |
| Phase | NA |
What the finished NCT02579421 record still lists
NCT02579421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02579421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02579421 about?
NCT02579421 is a clinical study titled "Hormones and Reduction in Co-users of Marijuana and Nicotine". The purpose of this study is to examine the role of progesterone (a naturally occurring hormone found in both men and women) on reducing marijuana use. The investigators will see if progesterone effects impulsivity, withdrawal, mood and stress during marijuana cessation.
What is the current status of trial NCT02579421?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2015-11. Estimated completion is 2017-07-27.
What interventions are being tested in trial NCT02579421?
The interventions under investigation include: placebo (DRUG), Progesterone (DRUG).
Who is sponsoring clinical trial NCT02579421?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02579421's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia